Targeted therapies directed at tumour cells harbouring epidermal growth factor receptor (EGFR) gene mutations, anaplastic lymphoma kinase (ALK) gene rearrangements, ROS proto-oncogene 1 (ROS1) gene fusions, and B-Raf proto-oncogene (BRAF) gene mutations have produced impressive results [6–9]. This evidence concerns the gene ALK and neoplasm.